Crizotinib in ALK-positive lung cancer

被引：4
作者：
Girard, Nicolas [1 ]
机构：
[1] Louis Pradel Hosp, F-69500 Bron, France
来源：
LANCET ONCOLOGY | 2012年 / 13卷 / 10期
关键词：
ANAPLASTIC LYMPHOMA; CELL; KINASE;
D O I：
10.1016/S1470-2045(12)70375-3
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：962 / 963
页数：2
相关论文
共 50 条
  • [41] Hyperactivated STAT3 in ALK-positive diffuse large B-cell lymphoma with clathrin-ALK fusion
    Momose, Shuji
    Tamaru, Jun-ichi
    Kishi, Hirohisa
    Mikata, Ittaku
    Mori, Masaya
    Toyozumi, Yasuo
    Itoyama, Shinji
    HUMAN PATHOLOGY, 2009, 40 (01) : 75 - 82
  • [42] Distinct benefit from crizotinib in lung cancer patients carrying distinct ALK translocations: is fluorescent hybridization in situ testing still sufficient to guide clinical decisions?
    Mitiushkina, Natalia V.
    Imyanitov, Evgeny N.
    TRANSLATIONAL CANCER RESEARCH, 2016, 5 : S1393 - S1395
  • [43] ALK-positive histiocytosis: a new clinicopathologic spectrum highlighting neurologic involvement and responses to ALK inhibition
    Kemps, Paul G.
    Picarsic, Jennifer
    Durham, Benjamin H.
    Helias-Rodzewicz, Zofia
    Hiemcke-Jiwa, Laura
    van den Bos, Cor
    van de Wetering, Marianne D.
    van Noesel, Carel J. M.
    van Laar, Jan A. M.
    Verdijk, Robert M.
    Flucke, Uta E.
    Hogendoorn, Pancras C. W.
    Woei-A-Jin, F. J. Sherida H.
    Sciot, Raf
    Beilken, Andreas
    Feuerhake, Friedrich
    Ebinger, Martin
    Mohle, Robert
    Fend, Falko
    Bornemann, Antje
    Wiegering, Verena
    Ernestus, Karen
    Mery, Tina
    Gryniewicz-Kwiatkowska, Olga
    Dembowska-Baginska, Bozenna
    Evseev, Dmitry A.
    Potapenko, Vsevolod
    Baykov, Vadim V.
    Gaspari, Stefania
    Rossi, Sabrina
    Gessi, Marco
    Tamburrini, Gianpiero
    Heritier, Sebastien
    Donadieu, Jean
    Bonneau-Lagacherie, Jacinthe
    Lamaison, Claire
    Farnault, Laure
    Fraitag, Sylvie
    Jullie, Marie-Laure
    Haroche, Julien
    Collin, Matthew
    Allotey, Jackie
    Madni, Majid
    Turner, Kerry
    Picton, Susan
    Barbaro, Pasquale M.
    Poulin, Alysa
    Tam, Ingrid S.
    El Demellawy, Dina
    Empringham, Brianna
    BLOOD, 2022, 139 (02) : 256 - 280
  • [44] Use of minimal disseminated disease and immunity to NPM-ALK antigen to stratify ALK-positive ALCL patients with different prognosis
    Mussolin, L.
    Damm-Welk, C.
    Pillon, M.
    Zimmermann, M.
    Franceschetto, G.
    Pulford, K.
    Reiter, A.
    Rosolen, A.
    Woessmann, W.
    LEUKEMIA, 2013, 27 (02) : 416 - 422
  • [45] Inhibition of Mitogen-Activated Protein Kinase Kinase Alone and in Combination with Anaplastic Lymphoma Kinase (ALK) Inhibition Suppresses Tumor Growth in a Mouse Model of ALK-Positive Lung Cancer
    Shrestha, N.
    Bland, A. R.
    Bower, R. L.
    Rosengren, R. J.
    Ashton, J. C.
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2020, 374 (01) : 134 - 140
  • [46] Blockade of crizotinib-induced BCL2 elevation in ALK-positive anaplastic large cell lymphoma triggers autophagy associated with cell death
    Torossian, Avedis
    Broin, Nicolas
    Frentzel, Julie
    Daugrois, Camille
    Gandarillas, Sarah
    Al Saati, Talal
    Lamant, Laurence
    Brousset, Pierre
    Giuriato, Sylvie
    Espinos, Estelle
    HAEMATOLOGICA, 2019, 104 (07) : 1428 - 1439
  • [47] Clinical effect of crizotinib on lung cancer patients with EML4-ALK fusion gene mutation
    Wang, Zhiyong
    Wang, Wei
    Kong, Xiaodong
    Li, Guangxu
    Yang, Weiwei
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2019, 12 (09): : 11632 - 11638
  • [48] Combined effect of ALK and MEK inhibitors in EML4-ALK-positive non-small-cell lung cancer cells
    Tanizaki, J.
    Okamoto, I.
    Takezawa, K.
    Sakai, K.
    Azuma, K.
    Kuwata, K.
    Yamaguchi, H.
    Hatashita, E.
    Nishio, K.
    Janne, P. A.
    Nakagawa, K.
    BRITISH JOURNAL OF CANCER, 2012, 106 (04) : 763 - 767
  • [49] Progression-Free and Overall Survival of Patients With ALK Rearrangement-Positive Non-Small Cell Lung Cancer Treated Sequentially With Crizotinib and Alectinib
    Watanabe, Satomi
    Hayashi, Hidetoshi
    Okamoto, Kunio
    Fujiwara, Kimiko
    Hasegawa, Yoshikazu
    Kaneda, Hiroyasu
    Tanaka, Kaoru
    Takeda, Masayuki
    Nakagawa, Kazuhiko
    CLINICAL LUNG CANCER, 2016, 17 (06) : 528 - 534
  • [50] Expression of mucins (MUC1, MUC2, MUC5AC and MUC6) in ALK-positive lung cancer: Comparison with EGFR-mutated lung cancer
    Lee, Hong Kyu
    Kwon, Mi Jung
    Seo, Jinwon
    Kim, Jeong Won
    Hong, Mineui
    Park, Hye-Rim
    Min, Soo Kee
    Choe, Ji-Young
    Ra, Yong Joon
    Jang, Seung Hun
    Hwang, Yong Il
    Kim, Ho Young
    Min, Kyueng-Whan
    PATHOLOGY RESEARCH AND PRACTICE, 2019, 215 (03) : 459 - 465
12345